Antipodes Partners LTD Gilead Sciences, Inc. Transaction History

Antipodes Partners LTD

$2.83 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$77.31 - $88.08 $8.67 Million - $9.88 Million	-112,203 Reduced 8.52%	1,204,538 $99.9 Million
Q4 2022 Feb 08, 2023	BUY	$62.32 - $89.47 $15.6 Million - $22.4 Million	249,941 Added 23.43%	1,316,741 $113 Million
Q3 2022 Nov 10, 2022	BUY	$59.54 - $68.01 $63.5 Million - $72.6 Million	1,066,800 New	1,066,800 $65.8 Million
Q4 2020 Feb 16, 2021	SELL	$56.65 - $64.55 $20.1 Million - $22.9 Million	-355,411 Closed	0 $0
Q3 2020 Nov 10, 2020	SELL	$62.1 - $78.08 $33.7 Million - $42.4 Million	-542,431 Reduced 60.41%	355,411 $22.5 Million
Q2 2020 Jul 30, 2020	BUY	$72.34 - $84.0 $540,741 - $627,900	7,475 Added 0.84%	897,842 $69.1 Million
Q1 2020 May 07, 2020	SELL	$62.63 - $80.22 $38.8 Million - $49.6 Million	-618,729 Reduced 41.0%	890,367 $66.6 Million
Q4 2019 Feb 05, 2020	SELL	$61.62 - $67.78 $19.4 Million - $21.4 Million	-315,194 Reduced 17.28%	1,509,096 $98.1 Million
Q3 2019 Nov 06, 2019	SELL	$62.51 - $69.0 $3.11 Million - $3.43 Million	-49,715 Reduced 2.65%	1,824,290 $116 Million
Q2 2019 Aug 14, 2019	BUY	$61.87 - $69.38 $29.6 Million - $33.2 Million	479,034 Added 34.34%	1,874,005 $0
Q1 2019 May 02, 2019	SELL	$62.53 - $70.05 $19.1 Million - $21.4 Million	-304,953 Reduced 17.94%	1,394,971 $90.7 Million
Q4 2018 Feb 08, 2019	SELL	$60.54 - $79.0 $13.2 Million - $17.3 Million	-218,787 Reduced 11.4%	1,699,924 $106 Million
Q3 2018 Nov 21, 2018	SELL	$71.28 - $78.92 $11.4 Million - $12.6 Million	-159,846 Reduced 7.69%	1,918,711 $148 Million
Q2 2018 Jul 31, 2018	SELL	$64.88 - $75.68 $40.7 Million - $47.5 Million	-627,295 Reduced 23.18%	2,078,557 $147 Million
Q1 2018 Apr 13, 2018	BUY	$72.84 - $88.8 $66.2 Million - $80.8 Million	909,370 Added 50.62%	2,705,852 $204 Million
Q4 2017 Jan 18, 2018	BUY	$71.15 - $83.52 $36.9 Million - $43.3 Million	518,890 Added 40.61%	1,796,482 $129 Million
Q3 2017 Oct 12, 2017	BUY	$72.11 - $85.47 $92.1 Million - $109 Million	1,277,592	1,277,592 $103 Million

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

Black Rock Inc. New York, NY

121M
Shares

$11.2 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$10.7 Billion
0.18% of portfolio
Capital World Investors Los Angeles, CA

76.5M
Shares

$7.09 Billion
1.03% of portfolio
Capital Research Global Investors Los Angeles, CA

61.8M
Shares

$5.72 Billion
1.12% of portfolio
State Street Corp Boston, MA

60.2M
Shares

$5.57 Billion
0.21% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Antipodes Partners LTD, based on Form 13F filings with the SEC.

News

Stay updated on Antipodes Partners LTD with notifications on news.

Account